Scientific publications

October 2025
Longitudinal changes in circulating tumor DNA in a phase 1 dose escalation study of micvotabart pelidotin, a first-in-human ADC targeting EDB+FN – Abstract Number: 1004
ESMO Poster
April 2025
The combination of anti-PD1 and a mouse analog of PYX-201, an antibody-drug conjugate targeting the extra-domain B splice variant of fibronectin (EDB+FN), shows greater anti-tumor efficacy than either treatment alone – Abstract Number: 3137
Poster
April 2025
Evaluation of PYX-201, an EDB+FN-targeting ADC, in a comprehensive PDX mini-trial study enables identification of gene signatures associated with anti-tumor activity – Abstract Number: 3120
Poster
November 2024
Sarcomas express extra domain B of fibronectin and preclinical patient-derived xenograft models of several sarcoma subtypes are sensitive to the stroma targeting antibody drug conjugate PYX-201 – Abstract #: 1854935
CTOS Poster
November 2024
Associations of the immunomodulatory molecule Siglec-15 gene and protein expression to immune gene signatures as a potential biomarker for Siglec-15 targeted therapy in non-small cell lung cancer – Abstract #: 219
SITC Poster
November 2024
Characterization and prevalence of the novel immunomodulatory protein Siglec-15 expression in tumor cells and macrophages across multiple solid tumor indications – Abstract # 521
SITC Poster
November 2024
PYX-106, a highly differentiated anti-Siglec-15 monoclonal antibody, reverses Siglec-15 mediated immune suppression and enhances cytotoxic activity in human lymphocytes – Abstract #: 567
SITC Poster
April 2024
PYX-201, EDB+FN is an attractive target in oncology: Insights from protein expression analysis of solid tumors – Abstract Number: 2908
AACR Poster
April 2024
PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models – Abstract Number: 742
AACR Poster
April 2024
Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells – Abstract Number: 4837
AACR 2014 Pfizer Poster